| BIOMARIN PHAR. DL-,001 | 100.44 / +0.64% |
| Date/Time | 08/07 / 19:50 |
| Chg. / Chg.(%) | 0.64 / +0.64% |
| Bid | - |
| Ask | - |
| Open | 100.20 |
| Previous Close | 99.80 |
| High | 100.44 |
| Low | 100.12 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 4 |
| ISIN | US09061G1013 |
| Security | BM8 |
| Exchange | Düsseldorf |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 101.02 |  |
|
| NASDAQ | 118.6700 | |
754,348 |
| IEX | 118.69 | |
67,621 |
| Cboe US | 118.73 | |
39,786 |
| Stuttgart | 100.440 | |
200 |
| TradeGate | 101.880 |  |
80 |
| Frankfurt | 100.3800 | |
0 |
| Berlin | 100.34 | |
0 |
| München | 101.56 | |
0 |
| Düsseldorf | 100.44 | |
0 |
| Vienna Globa.. | 101.92 | |
0 |
| gettex | 100.480 | |
|
| Mexico | 2,683.52 | 30 | |
| London Inter.. | 126.85 | 11,082 |
News
- Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire
Real-time